Targeted Oncology
Targeted Oncology
Targeted Oncology

Specialties

Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Targeted BRAF/MEK Inhibitor Combination Achieves Long-Term Survival in Melanoma
More than one-fourth of patients with advanced BRAF V600-mutant melanoma remained alive at 5 years after treatment with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), long-term follow-up from a randomized trial showed.
Immunotherapy Combinations Have Mechanistic Rationale in Ovarian Cancer
Immunotherapy combinations with PARP inhibitors or checkpoint inhibitors may represent the future of treatment for patients with ovarian cancer, said Samir N. Khleif, MD, during the 2017 ASCO Annual Meeting.
EU Recommends Ribociclib for Approval in Frontline HR+/HER2- Breast Cancer
Ribociclib has been recommended for approval by the Committee for Medicinal Products for Human Use, a part of the European Medicines Agency, for use in combination with an aromatase inhibitor as a first-line treatment for postmenopausal women with HR-positive /HER2-negative locally advanced or metastatic breast cancer.
 
McAneny Chosen as President-Elect of American Medical Association
Barbara L. McAneny, MD, FASCO, MACP, has been elected president-elect of the American Medical Association. Following a year-long term as president-elect, McAneny will assume the role of AMA president in June 2018.
Senate Healthcare Bill is a Disappointment, ASCO Says
A healthcare bill has been introduced by the Senate Republicans that would revise many of the changes imposed by the Patient Protection and Affordable Care Act, cutting federal support for Medicaid and repealing the individual and employer mandates for having and providing insurance.
Dabrafenib/Trametinib Combo Approved by FDA for BRAF+ NSCLC
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) has been approved by the FDA for the treatment of patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).
View More >

Features

Third Daratumumab Triplet Approved by FDA for Multiple Myeloma
Third Daratumumab Triplet Approved by FDA for Multiple Myeloma
Daratumumab (Darzalex) has been approved by the FDA for use in combination with pomalidomide (Pomalyst) and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies.
Ceritinib Approved by the FDA for Frontline ALK+ NSCLC
Ceritinib (Zykadia) has been approved by the FDA for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer.
Nivolumab Granted FDA's Priority Review for Liver Cancer
Nivolumab (Opdivo) has been granted a priority review designation by the FDA for use as a treatment for patients with hepatocellular carcinoma (HCC) following prior sorafenib.
Entrectinib Granted Breakthrough Designation by FDA for NTRK+ Solid Tumors
Entrectinib has been granted breakthrough therapy designation by the FDA for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors.
Brigatinib Approved by FDA for ALK-Positive NSCLC
Brigatinib (Alunbrig) has been granted an accelerated approval by the FDA as a treatment for patients with metastatic ALK-positive non-small cell lung cancer who are resistant to prior crizotinib.
Publications